BioSkryb Inks $11.5M Seed Round

This Seed round was led by the venture capital firm Anzu Partners and included Wilson Sonsini Goodrich & Rosati. The funding will accelerate the BioSkryb Product Roadmap and its marketing efforts to enable enhanced levels of genomic and transcriptomic analyzes for translational research and clinical diagnosis.

“Existing DNA amplification systems simply cannot provide the level of coverage and accuracy that researchers need to fully understand the genomics of individual cells where the amount of available genetic material is minimal,” said Jay West, PhD, co-founder and Chief Executive Officer of BioSkryb. “This amplification technology provides an unprecedented level of clarity and paves the way for a new era of genomic research, especially for single cell genomics in cancer research and bacterial genomics. “That’s right.

BioSkryb’s proprietary genomic amplification technology allows scientists working with scarce genetic material to achieve high-quality gene sequencing data. The technology ensures uniform coverage of almost the entire genome, allowing unparalleled accuracy in the DNA variant called The technology will support a new wave of single cell and low DNA input genomics applications in various areas of life sciences research, including cancer biology, microbiology and genetics.

“Bringing genetics to cellular level will lead to unforeseen discoveries about normal biology as well as human diseases such as cancer,” said Charles Gawad, MD/PhD, co-founder of BioSkryb and physician-scientist at Stanford University. “The challenge was that the quality of the data produced from existing genome amplification methods is insufficient to perform these types of studies. BioSkryb’s new, much more accurate genome amplification technology solves this problem and will accelerate our understanding of human and bacterial genetics, and will ultimately be used to develop single-cell diagnostics for oncology and other areas of medicine. “That’s right.

The company also announced the appointment of William E Evans, PharmD, Siddhartha C Kadia, PhD to the Board of Directors Dr. Dr. Evans has served as St. Jude Children’s Research Hospital was the fifth president and CEO from 2004 to 2014 and currently holds the St. Jude Endowed Chair of Pharmacogenomics Dr. Dr. Kadia previously served as President and CEO of EAG Laboratories in San Diego, CA, and President of Life Sciences Division at Life Technologies Corporation, a company that was acquired by Thermo Fisher in 2014.

“Dr. Evans and Kadia each bring valuable leadership experience to BioSkryb for decades, and we are pleased that they are joining the Board of Directors to help the company grow and commercialize its technology globally,” said David Michael, Managing Partner of Anzu Partners.

For more information on BioSkryb and its technology, please visit: https://bioskryb Come on,

BioSkryb will be presenting at the Advances in Genome Biology and Technology (AGBT) conference on 23-26 February 2020 in Marco Island, FL.

About BioScrib
BioSkryb is a venture-backed developer of genomic amplification technologies that deliver unprecedented coverage and fidelity to various gene sequencing applications. Its proprietary genome amplification technology was developed in St. Jude Children’s Research Hospital, Memphis, TN For further information, please visit: https://www Bioscrib Com/Com

About Partners of Anzu
Anzu Partners is a venture capital and private equity firm that invests in advanced industrial technologies. Anzu teams up with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity and operations. Visit https://anzupartners for more information. Come on, @anzupartners on Twitter

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioSkryb/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co